# Sildenafil for the Treatment of Lymphatic Malformations

> **NCT02335242** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 22 (actual)

## Conditions studied

- Lymphatic Malformations
- Lymphatic Diseases

## Interventions

- **DRUG:** Sildenafil 20 mg tablets
- **OTHER:** Placebo tablets (resembling Revatio)

## Key facts

- **NCT ID:** NCT02335242
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-23
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02335242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02335242, "Sildenafil for the Treatment of Lymphatic Malformations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02335242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*